- Home
- COOK vs CRVS Comparison
COOK vs CRVS Comparison
Compare COOK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- CRVS
- Stock Information
- Founded
- COOK 1985
- CRVS 2014
- Country
- COOK United States
- CRVS United States
- Employees
- COOK N/A
- CRVS N/A
- Industry
- COOK Wholesale Distributors
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- COOK Consumer Discretionary
- CRVS Health Care
- Exchange
- COOK Nasdaq
- CRVS Nasdaq
- Market Cap
- COOK 406.5M
- CRVS 451.0M
- IPO Year
- COOK 2021
- CRVS 2016
- Fundamental
- Price
- COOK $2.98
- CRVS $8.19
- Analyst Decision
- COOK Buy
- CRVS Buy
- Analyst Count
- COOK 7
- CRVS 4
- Target Price
- COOK $3.83
- CRVS $12.83
- AVG Volume (30 Days)
- COOK 159.0K
- CRVS 1.1M
- Earning Date
- COOK 11-06-2024
- CRVS 11-12-2024
- Dividend Yield
- COOK N/A
- CRVS N/A
- EPS Growth
- COOK N/A
- CRVS N/A
- EPS
- COOK N/A
- CRVS N/A
- Revenue
- COOK $598,914,000.00
- CRVS N/A
- Revenue This Year
- COOK $0.97
- CRVS N/A
- Revenue Next Year
- COOK $4.69
- CRVS N/A
- P/E Ratio
- COOK N/A
- CRVS N/A
- Revenue Growth
- COOK 3.17
- CRVS N/A
- 52 Week Low
- COOK $1.97
- CRVS $1.30
- 52 Week High
- COOK $3.97
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- COOK 39.96
- CRVS 51.74
- Support Level
- COOK $2.91
- CRVS $8.67
- Resistance Level
- COOK $3.59
- CRVS $10.00
- Average True Range (ATR)
- COOK 0.16
- CRVS 0.84
- MACD
- COOK -0.01
- CRVS -0.18
- Stochastic Oscillator
- COOK 9.56
- CRVS 18.10
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).